Kate is an experienced corporate lawyer with deep expertise in M&A (public and private) and equity capital markets, acting for corporates and private capital clients across the technology, healthcare and energy sectors.
She has extensive experience in ECM transactions including IPOs, rights issues, placements and share purchase plans. She also specialises in public and private M&A transactions including takeover bids, schemes of arrangement and private treaty transactions.
Kate acts for ASX-listed companies in relation to their corporate transactions and also acts for private equity and venture capital firms in relation to their Australian investments. She has previously worked for major Australian banks in their in-house M&A legal teams.
Work highlights
Protecht Group
On its sale to PSG Equity for $445 million.
Deloitte
Acquisition of PwC's interest in Yamagigu Consulting.
LiveHire Limited (ASX:LVH)
Sale to HumanForce (Accel-KKR portfolio company) by way of an on-market takeover bid and subsequent rights offering.
Novo Resources Corp. (ASX: NVO, TSX: NVO, OTCQX: NSRPF)
IPO and dual listing of its CDIs on the ASX in 2023.
CurveBeam AI Limited (ASX:CVB)
IPO and listing on the ASX in 2023 and 2024 entitlement offer.
Bionomics Limited (NASDAQ:BNOX, OTCQB:BNOEF)
2021 Nasdaq IPO and 2022 US capital raise, 2023 At-the-market (ATM) offering on Nasdaq and 2024 Private Investment in Public Equity (PIPE).